Systemic Lupus Erythematosus News and Research

RSS
Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.
Study highlights the interconnectedness of autoimmunity and cancer

Study highlights the interconnectedness of autoimmunity and cancer

The safety profile and the actual known adverse effects of COVID-19 vaccines in at-risk and healthy individuals

The safety profile and the actual known adverse effects of COVID-19 vaccines in at-risk and healthy individuals

Spontaneous coronary artery dissection: The leading cause of pregnancy-associated heart attacks

Spontaneous coronary artery dissection: The leading cause of pregnancy-associated heart attacks

Researchers discover the impact of microRNA on inflammation in lupus

Researchers discover the impact of microRNA on inflammation in lupus

Researchers review the association between endogenous retrovirus reactivation and aging

Researchers review the association between endogenous retrovirus reactivation and aging

Targeting T cell iron metabolism may offer a new approach for treating lupus

Targeting T cell iron metabolism may offer a new approach for treating lupus

Scientists use paleogenomics to trace 10,000 years of human immune system evolution

Scientists use paleogenomics to trace 10,000 years of human immune system evolution

COVID-19 outcomes in Rituximab treated patients

COVID-19 outcomes in Rituximab treated patients

Lupus Research Alliance announces recipients of the 2022 Distinguished Innovator Award focused on studying T cells in lupus

Lupus Research Alliance announces recipients of the 2022 Distinguished Innovator Award focused on studying T cells in lupus

CAR T therapy extends its reach beyond oncology

CAR T therapy extends its reach beyond oncology

PALS program effective in ensuring diverse representation in lupus clinical trials

PALS program effective in ensuring diverse representation in lupus clinical trials

Oral deucravacitinib shows promise in patients with active lupus

Oral deucravacitinib shows promise in patients with active lupus

First placebo-controlled long-term trial of anifrolumab shows positive results in patients with lupus

First placebo-controlled long-term trial of anifrolumab shows positive results in patients with lupus

Lower hydroxychloroquine dosing results in increased SLE-related hospitalizations, study finds

Lower hydroxychloroquine dosing results in increased SLE-related hospitalizations, study finds

Shared genetic effects between the autoimmune disease systemic lupus erythematosus and the clinical consequences of COVID-19

Shared genetic effects between the autoimmune disease systemic lupus erythematosus and the clinical consequences of COVID-19

Dietary components do not have impact on RMD outcomes

Dietary components do not have impact on RMD outcomes

The Black Death may have influenced the evolution of genes involved in immune responses against pathogens

The Black Death may have influenced the evolution of genes involved in immune responses against pathogens

Overview of the roles of neutrophils in systemic autoimmune and autoinflammatory diseases

Overview of the roles of neutrophils in systemic autoimmune and autoinflammatory diseases

Scientists receive $8.297 NIH grant to continue funding a Center for Lupus Research

Scientists receive $8.297 NIH grant to continue funding a Center for Lupus Research

Study reviews hydroxychloroquine and remdesivir antiviral potency against SARS‐CoV‐2

Study reviews hydroxychloroquine and remdesivir antiviral potency against SARS‐CoV‐2

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.